AMRI Acquired by The Carlyle Group and GTCR
The Carlyle Group and GTCR have completed a previously announced acquisition of AMRI, a contract research and manufacturing organization.
On Aug. 31, 2017, the previously announced acquisition of AMRI was completed by affiliates of investment firms The Carlyle Group and Golder, Thomas, Cressey, Rauner (GTCR) for $21.75 per share in cash. AMRI president and CEO William S. Marth will continue leading the company.
Initially announced in June 2017, the agreement was unanimously approved by the AMRI board of directors, which had recommended that shareholders vote in favor of the transaction.
AMRI is a contract research and manufacturing organization with 25 years of experience in the pharmaceutical and biopharmaceutical industries. The company specializes in combining science and technology from start to finish of the drug discovery and development process. Its services include discovery, development, analytical and solid state services, and API manufacturing and drug product solutions.
Source: AMRI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
